Measles Crisis: NanoViricides Proposes NV-387 as Potential Solution

Amid the measles outbreak, NanoViricides highlighted the urgent unmet need for approved antiviral treatments. President Dr. Anil Diwan emphasized NV-387, a broad-spectrum antiviral, as a promising candidate to address this gap. The drug has shown effectiveness against various viruses using heparan sulfate proteoglycans (HSPG), a mechanism also employed by the measles virus.

Current containment strategies face challenges due to measles' high contagion rate and the emergence of new viral genotypes. Vaccination remains crucial but insufficient for immediate outbreak control. NanoViricides is urging support for clinical trials of NV-387, which could augment public health responses.

Dr. Diwan expressed readiness to collaborate with the US Health and Human Services and emphasized NV-387's potential to offer immediate assistance in managing measles cases if successful in trials.